Clinical and biochemical outcome after hydroxocobalamin dose escalation in a series of patients with cobalamin C deficiency.

[1]  C. Venditti,et al.  Combined methylmalonic acidemia and homocystinuria, cblC type. II. Complications, pathophysiology, and outcomes , 2012, Journal of Inherited Metabolic Disease.

[2]  R. Chandler,et al.  Combined methylmalonic acidemia and homocystinuria, cblC type. I. Clinical presentations, diagnosis and management , 2012, Journal of Inherited Metabolic Disease.

[3]  D. Jacobsen,et al.  The MMACHC proteome: hallmarks of functional cobalamin deficiency in humans. , 2011, Molecular genetics and metabolism.

[4]  J. Straková,et al.  Inhibition of betaine-homocysteine S-methyltransferase in rats causes hyperhomocysteinemia and reduces liver cystathionine β-synthase activity and methylation capacity. , 2011, Nutrition research.

[5]  D. Martinelli,et al.  Cobalamin C defect: natural history, pathophysiology, and treatment , 2011, Journal of Inherited Metabolic Disease.

[6]  C. Fusco,et al.  Early onset methylmalonic aciduria and homocystinuria cblC type with demyelinating neuropathy. , 2010, Pediatric neurology.

[7]  G. Diaz,et al.  Newborn screening and early biochemical follow-up in combined methylmalonic aciduria and homocystinuria, cblC type, and utility of methionine as a secondary screening analyte. , 2010, Molecular genetics and metabolism.

[8]  A. Hamosh,et al.  Hydroxocobalamin dose escalation improves metabolic control in cblC , 2009, Journal of Inherited Metabolic Disease.

[9]  G. Shepherd,et al.  Role of Hydroxocobalamin in Acute Cyanide Poisoning , 2008, The Annals of pharmacotherapy.

[10]  S. Hecht,et al.  Changes in blood pressure after administration of hydroxocobalamin: Relationship to changes in plasma cobalamins-(III) concentrations in healthy volunteers , 2008, Clinical toxicology.

[11]  S. Kölker,et al.  Neurodegeneration and chronic renal failure in methylmalonic aciduria—A pathophysiological approach , 2008, Journal of Inherited Metabolic Disease.

[12]  S. Blaser,et al.  Late‐onset cobalamin‐C disorder: A challenging diagnosis , 2007, American journal of medical genetics. Part A.

[13]  G. Golor,et al.  Safety of Hydroxocobalamin in Healthy Volunteers in a Randomized, Placebo-Controlled Study , 2006, Clinical toxicology.

[14]  E. Shoubridge,et al.  Identification of the gene responsible for methylmalonic aciduria and homocystinuria, cblC type , 2006, Nature Genetics.

[15]  E. R. Baumgartner,et al.  Cobalamin disorder Cbl-C presenting with late-onset thrombotic microangiopathy. , 2002, American journal of medical genetics.

[16]  O. Bodamer,et al.  Practical Management of Combined Methylmalonicaciduria and Homocystinuria , 2002, Journal of child neurology.

[17]  M. Marble,et al.  Long-term outcome in treated combined methylmalonic acidemia and homocystinemia , 1999, Genetics in Medicine.

[18]  C. Roe,et al.  Therapeutic approaches to cobalamin-C methylmalonic acidemia and homocystinuria. , 1988, The Journal of pediatrics.

[19]  H. Willard,et al.  Cobalamin coenzyme synthesis in normal and mutant human fibroblasts. Evidence for a processing enzyme activity deficient in cblC cells. , 1979, The Journal of biological chemistry.